Last week, families of children and young adults with Progeria welcomed the news that we are one step closer to the first approved treatment for this ultra-rare, devastating condition that causes ...

Progeria, also known as Hutchinson-Gilford progeria syndrome, is a rare disorder that profoundly reshapes the lives of those affected. This condition manifests through a paradox of youth and premature ...

Beandri Booysen, a teenage girl who radiated an undeniable “hope and joy” for life despite suffering from an extremely rare aging disease, passed away just days before Christmas. She was 19 years old.

Biomedical engineers at Duke University constructed an advanced disease model for blood vessels prompting insights into Hutchinson-Gilford progeria syndrome, according to a study published in Stem ...

Partnership marks a critical step toward clinical development of an AAV gene therapy using a base editing approach designed to target the genetic cause of Hutchinson-Gilford Progeria Syndrome Forge ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

A University of Maryland-led discovery could spur the development of new and improved treatments for Hutchinson-Gilford progeria syndrome (HGPS), a rare genetic disorder with no known cure that causes ...

Scientists at the Centro Nacional de Investigaciones Cardiovasculares (CNIC) have identified the process of endothelial-to-mesenchymal transition (EndMT) as a novel mechanism in premature ...

New research published in JAMA reports that lonafarnib, a farnesyltransferase inhibitor (FTI), extended survival in patients with Hutchinson-Gilford progeria syndrome (HGPS), or progeria. New research ...

The gene-editing method known as base editing might be a way to address the underlying cause of Hutchinson-Gilford progeria syndrome (HGPS or progeria), a rare genetic disease that leads to ...

PALO ALTO, Calif., Nov. 20, 2020 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare ...

Researchers have successfully used a DNA-editing technique to extend the lifespan of mice with the genetic variation associated with progeria, a rare genetic disease that causes extreme premature ...